Biocon’s Kirsty Makes History: First Interchangeable Insulin Aspart in America

Unknown Apr 02, 2026 1,150 Views

Biocon Biologics Ltd. achieved another key regulatory milestone with the U.S. FDA approval of Kirsty (Insulin Aspart-xjhz), the first and only biosimilar interchangeable of NovoLog in the U.S. market. The approval significantly strengthens Biocon's diabetes care business and reestablishes its...